Table 6. Inflammatory cytokine and prostacyclin release from HMVEC after stimulation of NOD1 or TLR4.

Analyte (pg/ml)	Treatment
	CTRL	iE-DAP (NOD1) 10 µg/ml	LPS (TLR4) 1 µg/ml
A
CXCL8	616.6±79.7	4639.0±365.2*	8712.3±737.6*
GM-CSF	12.5±2.6	93.8±11.7#	280.0±50.6#
IFNγ	0±0	3.1±0.9*	5.5±0.6*
IL12p70	5.1±2.2	18.4±2.0#	76.9±10.6#
IL-1β	0.5±0.3	5.4±0.7#	7.7±1.0#
IL-2	20.8±3.9	141.2±11.8*	258.8±20.5*
IL6	51.1±10.0	111.7±18.2	718.0±89.8*
IP-10	0.5±0.2	1.1±0.3	3.6±0.5*
TNFα	0.6±0.3	2.7±0.6#	5.3±1.5#
B
6-keto prostaglandin F1α	318.4±46.3	1322.2±108.2*	2029.3±175.0*

HMVEC were cultured for 24 hours in 96 well plates with media alone (CTRL), iE-DAP 10 µg/ml (NOD1) or LPS 1 µg/ml (TLR4). (A) Inflammatory cytokine release measured using the Human Pro-Inflammatory 9-PlexBase Kit from Meso Scale Discovery (MSD®). Results are expressed as mean ± SEM for n = 15. (B) 6-keto prostaglandin F1α release (breakdown product of Prostacyclin) measured by ELISA. Results are expressed as mean ± SEM for n = 15. Results analysed by one-way ANOVA with Dunnett’s multiple comparison test (*P<0.05) or by Kruskal-Wallis test with Dunn’s multiple comparison test for non-parametric data (^#P<0.05).